DK305884A
(en)
*
|
1983-06-24 |
1984-12-25 |
Yamanouchi Pharma Co Ltd |
PHENOXYDER DERIVATIVE, PROCEDURE FOR PREPARING THEREOF AND PHARMACEUTICAL PREPARATION CONTAINING SUCH DERIVATIVE
|
CN1003445B
(en)
*
|
1984-10-03 |
1989-03-01 |
武田药品工业株式会社 |
The preparation method of thiazolidine diketone derivative
|
US4812570A
(en)
*
|
1986-07-24 |
1989-03-14 |
Takeda Chemical Industries, Ltd. |
Method for producing thiazolidinedione derivatives
|
FI91869C
(en)
*
|
1987-03-18 |
1994-08-25 |
Tanabe Seiyaku Co |
Process for the preparation of benzoxazole derivatives as antidiabetic agents
|
HU203330B
(en)
*
|
1987-06-10 |
1991-07-29 |
Pfizer |
Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
|
GB8713861D0
(en)
*
|
1987-06-13 |
1987-07-15 |
Beecham Group Plc |
Compounds
|
EP0295828A1
(en)
*
|
1987-06-13 |
1988-12-21 |
Beecham Group Plc |
Novel compounds
|
US4798835A
(en)
*
|
1987-12-02 |
1989-01-17 |
Pfizer Inc. |
dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
|
US4791125A
(en)
*
|
1987-12-02 |
1988-12-13 |
Pfizer Inc. |
Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US4997948A
(en)
*
|
1989-10-27 |
1991-03-05 |
American Home Products |
5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
|
KR0170416B1
(en)
†
|
1990-02-09 |
1999-02-18 |
로버트 에이. 아미테이지 |
Use of insulin sensitizing agents to treat hypertension
|
US5356913A
(en)
*
|
1990-02-09 |
1994-10-18 |
The Upjohn Company |
Use of insulin sensitizing agents to treat hypertension
|
ATE205206T1
(en)
*
|
1990-04-27 |
2001-09-15 |
Sankyo Co |
BENZYLIDENTHIAZOLIDINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS LIPIDE PEROXIDE INHIBITORS
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
US5158966A
(en)
*
|
1991-02-22 |
1992-10-27 |
The University Of Colorado Foundation, Inc. |
Method of treating type i diabetes
|
US5441971A
(en)
*
|
1991-04-11 |
1995-08-15 |
The Upjohn Company |
Thiazolidinedione derivatives, production and use thereof
|
SK109993A3
(en)
*
|
1991-04-11 |
1994-12-07 |
Upjohn Co |
Thiazolidinedione derivatives producing and use thereof
|
US5183823A
(en)
*
|
1991-04-11 |
1993-02-02 |
Takeda Chemical Industries, Ltd. |
Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
|
FR2680512B1
(en)
*
|
1991-08-20 |
1995-01-20 |
Adir |
NOVEL 2,4-THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
ZA936492B
(en)
*
|
1992-09-10 |
1995-03-02 |
Lilly Co Eli |
Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
|
JP2845743B2
(en)
*
|
1992-12-28 |
1999-01-13 |
三菱化学株式会社 |
New naphthalene derivatives
|
US5594016A
(en)
*
|
1992-12-28 |
1997-01-14 |
Mitsubishi Chemical Corporation |
Naphthalene derivatives
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
US5457109A
(en)
*
|
1993-09-15 |
1995-10-10 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
ATE376829T1
(en)
*
|
1993-09-15 |
2007-11-15 |
Daiichi Sankyo Co Ltd |
USE OF THIAZOLIDINDIONES TO PREVENT OR DELAY THE OCCURMENT OF NONINSULIN DEPENDENT DIABETES MELLITUS (NIDDM)
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
ES2135711T4
(en)
*
|
1994-03-08 |
2000-01-01 |
American Home Prod |
DERIVATIVES OF TIAZOLIDINDIONA AS ANTI-HYPERGLYCEMIC AGENTS.
|
US6251928B1
(en)
|
1994-03-16 |
2001-06-26 |
Eli Lilly And Company |
Treatment of alzheimer's disease employing inhibitors of cathepsin D
|
CN1071333C
(en)
*
|
1994-10-20 |
2001-09-19 |
日本化学医药株式会社 |
Quinoline derivative
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
WO1996035688A1
(en)
*
|
1995-05-08 |
1996-11-14 |
Nippon Chemiphar Co., Ltd. |
2,4-thiazolidinedione or oxazolidinedione derivatives and hypoglycemic agent
|
TWI238064B
(en)
|
1995-06-20 |
2005-08-21 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
RU2158607C2
(en)
*
|
1995-07-03 |
2000-11-10 |
Санкио Компани Лимитед |
Arteriosclerosis and xanthoma treatment
|
EP0783888A1
(en)
*
|
1995-12-26 |
1997-07-16 |
Sankyo Company Limited |
Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
|
NZ314406A
(en)
*
|
1996-03-18 |
2000-12-22 |
Sankyo Co |
Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
|
JP2000511883A
(en)
*
|
1996-04-19 |
2000-09-12 |
ノボ ノルディスク アクティーゼルスカブ |
Modulators of molecules with phosphotyrosine recognition units
|
US5958957A
(en)
*
|
1996-04-19 |
1999-09-28 |
Novo Nordisk A/S |
Modulators of molecules with phosphotyrosine recognition units
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
US5952509A
(en)
*
|
1996-06-27 |
1999-09-14 |
Takeda Chemical Industries, Ltd. |
Production of benzaldehyde compounds
|
WO1998020871A1
(en)
*
|
1996-11-08 |
1998-05-22 |
Nippon Chemiphar Co., Ltd. |
Visceral fat lowering agent
|
EP1006794B1
(en)
*
|
1997-03-12 |
2007-11-28 |
Robert W. Esmond |
A method for treating or preventing alzheimer's disease
|
US5908859A
(en)
*
|
1997-08-11 |
1999-06-01 |
Eli Lilly And Company |
Benzothiophenes for inhibiting hyperlipidemia
|
HUP9902721A2
(en)
*
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Concentrated fabric softening composition and highly unsaturated fabric softener compound therefor
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
WO1999030739A1
(en)
*
|
1997-12-16 |
1999-06-24 |
Sankyo Company, Limited |
Leukemia remedy
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
EP1143953A3
(en)
*
|
1998-11-20 |
2002-02-06 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
DE60035271D1
(en)
|
1999-04-28 |
2007-08-02 |
Inst Med Molecular Design Inc |
Pyrimidincarbonsäurederivate
|
JP2001072592A
(en)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
Telomerase inhibitor
|
ID29875A
(en)
*
|
1999-07-01 |
2001-10-18 |
Geron Corp Cs |
TELOMERAGE OBSTACLES AND USE METHODS
|
US7390824B1
(en)
*
|
1999-09-07 |
2008-06-24 |
Bristol-Myers Squibb Company |
Method for treating diabetes employing an aP2 inhibitor and combination
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
CO5200844A1
(en)
|
1999-09-17 |
2002-09-27 |
Novartis Ag |
A COMBINATION THAT INCLUDES NATEGLINED AND WHEN AT LEAST ANOTHER ANTI-DIABETIC COMPOUND USED FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR OF A DISEASE OR CONDITION ASSOCIATED WITH DIBETES
|
ES2156574B1
(en)
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
NEW DERIVATIVES OF TIAZOLIDINDIONA AS ANTIDIABETIC AGENTS
|
CN1215059C
(en)
|
1999-12-03 |
2005-08-17 |
京都药品工业株式会社 |
Novel heterocyclic compounds and salts thereof and medicinal use of same
|
JP2003520226A
(en)
|
2000-01-21 |
2003-07-02 |
ノバルティス アクチエンゲゼルシャフト |
Combination comprising a dipeptidyl peptidase-IV inhibitor and an antidiabetic agent
|
US6958355B2
(en)
*
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6680387B2
(en)
*
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6784199B2
(en)
|
2000-09-21 |
2004-08-31 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
|
HUP0300475A3
(en)
*
|
2000-04-25 |
2004-10-28 |
Kyorin Seiyaku Kk |
Novel stable crystal of thiazolidinedione derivative and process for producing the same
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
EP1354602B1
(en)
*
|
2000-12-26 |
2006-10-04 |
Sankyo Company, Limited |
Medicinal compositions containing diuretic and insulin resistance-improving agent
|
CZ20032031A3
(en)
*
|
2001-01-26 |
2003-12-17 |
Schering Corporation |
Pharmaceutical preparation
|
AR034204A1
(en)
*
|
2001-01-26 |
2004-02-04 |
Schering Corp |
COMPOSITIONS AND COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES OF THE SAME WITH INHIBITOR (S) OF THE ABSORPTION OF THE STEROLS, AND THE USE OF THE SAME TO PREPARE MEDICINES FOR THE TREATMENT FOR VASCULAR INDICATIONS
|
AU2002247019C1
(en)
*
|
2001-01-26 |
2017-05-11 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
KR20080067717A
(en)
*
|
2001-01-26 |
2008-07-21 |
쉐링 코포레이션 |
A pharmaceutical composition for treating vascular conditions, comprising sterol absorption inhibitor(s) and blood modifier(s)
|
DK1363668T3
(en)
*
|
2001-01-26 |
2007-11-05 |
Schering Corp |
Combinations of bile acid complexing agent (s) and sterol absorption inhibitor (s) and treatment of vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
CZ305202B6
(en)
*
|
2001-01-26 |
2015-06-10 |
Merck Sharp & Dohme Corp. |
Pharmaceutical composition
|
PT1757606E
(en)
*
|
2001-02-24 |
2009-05-26 |
Boehringer Ingelheim Pharma |
Xanthinderivatives for use as medical agents and the preparation thereof
|
KR200249057Y1
(en)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
Sewage backflow integrated into the lid and base. Odor Prevention Device
|
CN100577175C
(en)
*
|
2001-04-04 |
2010-01-06 |
奥索-麦克尼尔药品公司 |
Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
CA2445322C
(en)
*
|
2001-04-25 |
2011-06-14 |
Takeda Chemical Industries, Ltd. |
Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
|
EP1387843B1
(en)
*
|
2001-04-26 |
2007-02-28 |
Zentiva, a.s. |
Method for obtaining pioglitazone as an antidiabetic agent
|
PL367676A1
(en)
*
|
2001-05-29 |
2005-03-07 |
Kyoto Pharmaceutical Industries, Ltd. |
Novel heterocyclic derivatives and medicinal use thereof
|
RU2299197C2
(en)
*
|
2001-05-29 |
2007-05-20 |
Киото Фармасьютикал Индастриз, Лтд. |
Heterocyclic compounds, pharmaceutical composition and pharmaceutical agent based on thereof and method of treatment
|
CA2456034A1
(en)
*
|
2001-08-03 |
2003-02-20 |
Takeda Chemical Industries, Ltd. |
Sustained-release medicines
|
JP2005504091A
(en)
*
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
Treatment of xanthomas with azetidinone as a sterol absorption inhibitor
|
HUP0401501A3
(en)
*
|
2001-09-21 |
2012-02-28 |
Schering Corp |
Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US7135485B2
(en)
*
|
2001-09-28 |
2006-11-14 |
Teva Pharmaceutical Industries Ltd. |
Pioglitazone hydrochloride
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
AU2002366812A1
(en)
*
|
2001-12-20 |
2003-07-09 |
Teva Pharmaceutical Industries Ltd. |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
US20050187258A1
(en)
*
|
2001-12-20 |
2005-08-25 |
Ben-Zion Dolitzky |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
ITRM20020016A1
(en)
|
2002-01-15 |
2003-07-15 |
Sigma Tau Ind Farmaceuti |
FENYL ACID DERIVATIVES (ALCHYL) CARBOXYL AND DYNIC PHENYLALKYL THEROCYCLIC DERIVATIVES, THEIR USE AS MEDICATIONS WITH HYPOGLYCEMIC ACTIVITY
|
JPWO2003062427A1
(en)
*
|
2002-01-23 |
2005-05-26 |
山之内製薬株式会社 |
Screening method for insulin sensitizers
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(en)
*
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
Thiazolidinedione derivatives and pharmaceutical composition comprising the same
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
EP1515701B1
(en)
|
2002-06-17 |
2014-09-17 |
Inventia Healthcare Private Limited |
Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
|
US8993773B2
(en)
|
2002-07-16 |
2015-03-31 |
Cadila Healthcare Limited |
Process to prepare pioglitazone via several novel intermediates
|
EP1521753B1
(en)
|
2002-07-16 |
2007-09-05 |
Cadila Healthcare Ltd. |
A process to prepare pioglitazone via several intermediates.
|
US7407955B2
(en)
*
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
WO2004024059A2
(en)
*
|
2002-09-12 |
2004-03-25 |
Themis Laboratories Private Limited, |
Improved process for preparation of thiazolidinedione derivatives
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
KR20120034211A
(en)
|
2002-09-20 |
2012-04-10 |
안드렉스 랩스 엘엘씨 |
Pharmaceutical tablet
|
US7785627B2
(en)
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
EP1560579A1
(en)
*
|
2002-11-06 |
2005-08-10 |
Schering Corporation |
Cholesterol absorption inhibitors for the treatment of autoimmune disorders
|
US7208486B2
(en)
|
2003-03-07 |
2007-04-24 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
WO2004081002A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
JP2006519869A
(en)
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
Substituted azetidinone compounds, processes for preparing substituted azetidinone compounds, their formulations and uses
|
EP1608317B1
(en)
|
2003-03-25 |
2012-09-26 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2004108721A1
(en)
*
|
2003-04-01 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
|
ES2219180B1
(en)
*
|
2003-05-09 |
2006-03-01 |
Medichem, S.A. |
INTERMEDIATE COMPOUND USEFUL FOR THE PREPARATION OF PIOGLITAZONA.
|
JP2007502847A
(en)
*
|
2003-05-13 |
2007-02-15 |
シントン・ベスローテン・フェンノートシャップ |
Thiazolidinedione derivative and method for producing the compound
|
US7230016B2
(en)
*
|
2003-05-13 |
2007-06-12 |
Synthon Ip Inc. |
Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
|
SI1622899T1
(en)
*
|
2003-05-13 |
2007-10-31 |
Synthon Bv |
Pioglitazone sulfate, pharmaceutical compositions and their use
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
WO2004106542A1
(en)
*
|
2003-05-29 |
2004-12-09 |
Sankyo Company, Limited |
Insulin resistance curative and method of screening the same
|
EA009646B1
(en)
|
2003-05-30 |
2008-02-28 |
Рэнбакси Лабораториз Лтд. |
Substituted pyrrole derivatives and their use thereof as hmg-coa inhibitors
|
US7470700B2
(en)
|
2003-08-13 |
2008-12-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US20070078170A1
(en)
*
|
2003-08-28 |
2007-04-05 |
Khanduri Chandra H |
Process for the preparation of pioglitazone
|
WO2005021543A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Biocon Limited |
Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
|
JP2007505121A
(en)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
Dipeptidyl peptidase inhibitor
|
US7625916B2
(en)
*
|
2003-09-17 |
2009-12-01 |
Kaname Kawasugi |
Medicinal composition
|
EP1680189A2
(en)
*
|
2003-11-05 |
2006-07-19 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
EP1716144A2
(en)
*
|
2004-02-20 |
2006-11-02 |
Synthon B.V. |
Processes for making pioglitazone and compounds of the processes
|
AU2004318013B8
(en)
*
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005092382A1
(en)
*
|
2004-03-29 |
2005-10-06 |
Sankyo Company, Limited |
Therapeutic agent for diabetes containing insulin resistance improving agent
|
US7161756B2
(en)
*
|
2004-05-10 |
2007-01-09 |
Tandberg Data Storage Asa |
Method and system for communication between a tape drive and an external device
|
US20060025478A1
(en)
*
|
2004-07-27 |
2006-02-02 |
Keisuke Inoue |
Medicine for prevention or treatment of diabetes
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
JP4854511B2
(en)
*
|
2004-08-26 |
2012-01-18 |
武田薬品工業株式会社 |
Diabetes treatment
|
WO2006035459A1
(en)
*
|
2004-09-28 |
2006-04-06 |
Morepen Laboratories Limited |
An improved process for the production of derivatives of thiozolidinediones and their precursors
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
DE102004054054A1
(en)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
JP2008524331A
(en)
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
Dipeptidyl peptidase inhibitor
|
EP1874308A1
(en)
*
|
2005-03-08 |
2008-01-09 |
Nycomed GmbH |
Roflumilast for the treatment of diabetes mellitus
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
KR20080025662A
(en)
*
|
2005-03-18 |
2008-03-21 |
오키드 케미칼즈 앤드 파마수티컬즈 리미티드 |
Novel tyrosine derivatives
|
WO2006117654A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
Processes for the preparation of pioglitazone or salts thereof
|
JPWO2007007757A1
(en)
*
|
2005-07-12 |
2009-01-29 |
第一三共株式会社 |
Pharmaceutical composition containing a PPARγ agonist
|
US20090203744A1
(en)
*
|
2005-07-29 |
2009-08-13 |
Pande Y Surendrakumar Satyanarayan |
Novel pyridine derivatives
|
DE102005035891A1
(en)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
|
CA2622472C
(en)
*
|
2005-09-14 |
2013-11-19 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
CN101360723A
(en)
|
2005-09-16 |
2009-02-04 |
武田药品工业株式会社 |
Process for the preparation of pyrimidinedione derivatives
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
AU2006313430B2
(en)
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
CA2646149A1
(en)
*
|
2006-03-16 |
2007-09-27 |
Metabolic Solutions Development Company |
Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
|
WO2007109088A2
(en)
*
|
2006-03-16 |
2007-09-27 |
Metabolic Solutions Development Company |
Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
|
AU2007227581B2
(en)
|
2006-03-16 |
2012-11-08 |
Metabolic Solutions Development Company, Llc |
Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
|
PE20110235A1
(en)
*
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
CA2873524C
(en)
|
2006-05-04 |
2018-02-20 |
Boehringer Ingelheim International Gmbh |
A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
|
EP2037928B1
(en)
|
2006-06-26 |
2012-01-11 |
Amgen Inc. |
Methods for treating atherosclerosis
|
KR100791399B1
(en)
|
2006-09-06 |
2008-01-07 |
동우신테크 주식회사 |
Process for preparing of pioglitazone hcl
|
WO2008028914A1
(en)
|
2006-09-07 |
2008-03-13 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
US20080182880A1
(en)
*
|
2006-09-28 |
2008-07-31 |
Mailatur Sivaraman Mohan |
Pioglitazone composition
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
BRPI0720032A2
(en)
*
|
2006-12-13 |
2013-12-17 |
Gilead Sciences Inc |
COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PROCESS, FORMULATION OF AEROSOL, METHOD FOR PREVENTION AND TREATMENT OF PULMONARY INFLAMMATION, AND USE OF A COMPOUND.
|
WO2008075380A2
(en)
*
|
2006-12-21 |
2008-06-26 |
Ind-Swift Laboratories Limited |
Process for the preparation of thiazolidine derivatives
|
US20080176905A1
(en)
*
|
2007-01-22 |
2008-07-24 |
Santiago Ini |
Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
|
BRPI0807453B8
(en)
*
|
2007-02-01 |
2021-05-25 |
Takeda Pharmaceuticals Co |
solid preparation
|
KR101126383B1
(en)
|
2007-02-07 |
2012-04-12 |
교와 핫꼬 기린 가부시키가이샤 |
Tricyclic compounds
|
WO2008105326A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Ohara Chemical Industries, Ltd. |
Process for production of 2-imino-4-thiazolidinone derivative and 2,4-thiazolidinedione derivative
|
AR065670A1
(en)
|
2007-03-09 |
2009-06-24 |
Indigene Pharmaceuticals Inc |
COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
WO2008121563A2
(en)
|
2007-03-30 |
2008-10-09 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
WO2008124122A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent and glitazones
|
AU2008240158B2
(en)
|
2007-04-11 |
2014-07-10 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US20160331729A9
(en)
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
DK2170930T3
(en)
|
2007-06-04 |
2012-11-05 |
Synergy Pharmaceuticals Inc |
AGONISTS OF GUANYLATCYCLASE USED FOR THE TREATMENT OF GASTROINTESTINAL DISEASES, INFLAMMATION, CANCER AND OTHER DISEASES
|
EP2152663B1
(en)
|
2007-06-04 |
2014-03-19 |
Ben Gurion University of the Negev Research and Development Authority |
Tri-aryl compounds and compositions comprising the same
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2489730B1
(en)
|
2007-07-26 |
2015-12-30 |
Amgen, Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
ES2733348T3
(en)
*
|
2007-08-17 |
2019-11-28 |
Boehringer Ingelheim Int |
Purine derivatives for use in the treatment of diseases related to FAP
|
CN101848901B
(en)
|
2007-09-14 |
2012-11-21 |
新陈代谢解决方案开发公司 |
Thiazolidinedione analogues for the treatment of hypertension
|
US8304441B2
(en)
|
2007-09-14 |
2012-11-06 |
Metabolic Solutions Development Company, Llc |
Thiazolidinedione analogues for the treatment of metabolic diseases
|
US7960376B2
(en)
*
|
2007-09-14 |
2011-06-14 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
US8722710B2
(en)
|
2007-09-26 |
2014-05-13 |
Deuterx, Llc |
Deuterium-enriched pioglitazone
|
US20090118514A1
(en)
*
|
2007-11-06 |
2009-05-07 |
Raghupathi Reddy Anumula |
Processes for preparing pioglitazone and its pharmaceutically acceptable salts
|
JP5334422B2
(en)
*
|
2008-02-13 |
2013-11-06 |
株式会社トクヤマ |
Process for producing 5- {4- [2- (5-ethyl-2-pyridyl) ethoxy] benzyl} -2-imino-4-thiazolidinone
|
JP5197063B2
(en)
*
|
2008-02-21 |
2013-05-15 |
株式会社トクヤマ |
Process for producing methyl 2-bromo-3- {4- [2- (5-ethyl-2-pyridyl) ethoxy] phenyl} propionate
|
PE20140960A1
(en)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
FORMULATIONS INVOLVING A DPP4 INHIBITOR
|
WO2009133576A1
(en)
*
|
2008-04-28 |
2009-11-05 |
Erregierre S.P.A. |
A process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone
|
PE20100156A1
(en)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
NAFLD TREATMENT
|
JP2011522828A
(en)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
|
ES2624828T3
(en)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
BRPI0916997A2
(en)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
DPP-4 INHIBITOR AND ITS USE
|
WO2010016549A1
(en)
|
2008-08-06 |
2010-02-11 |
協和発酵キリン株式会社 |
Tricyclic compound
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
US8815508B2
(en)
|
2008-08-12 |
2014-08-26 |
Zinfandel Pharmaceuticals, Inc. |
Method of identifying disease risk factors
|
US20110190322A1
(en)
*
|
2008-08-14 |
2011-08-04 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
KR20110049779A
(en)
*
|
2008-09-02 |
2011-05-12 |
가부시끼가이샤 도꾸야마 |
Dehydrobromination inhibitor
|
CN102149407A
(en)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
Combination therapy for the treatment of diabetes and related conditions
|
CN102149669A
(en)
*
|
2008-10-10 |
2011-08-10 |
株式会社德山 |
Process for producing carbonyloxy compound
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JP5473303B2
(en)
*
|
2008-12-01 |
2014-04-16 |
株式会社トクヤマ |
Process for producing methyl 2-bromo-3- {4- [2- (5-ethyl-2-pyridyl) ethoxy] phenyl} propionate
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
BRPI0923121A2
(en)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Saline forms of organic compounds
|
AR074990A1
(en)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
|
KR20110110766A
(en)
*
|
2009-01-20 |
2011-10-07 |
가부시끼가이샤 도꾸야마 |
Method for inhibiting dehydrobromination of methyl 2-bromo-3-[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]propionate
|
JP2010208957A
(en)
*
|
2009-03-06 |
2010-09-24 |
Tokuyama Corp |
5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2-imino-4-thiazolidinone having crystal structure and method for producing the same
|
EP3398599A1
(en)
|
2009-03-11 |
2018-11-07 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
WO2010151711A1
(en)
*
|
2009-06-25 |
2010-12-29 |
Alkermes, Inc. |
Prodrugs of nh-acidic compounds
|
HRP20171415T4
(en)
|
2009-06-25 |
2023-03-03 |
Alkermes Pharma Ireland Limited |
Heterocyclic compounds for the treatment of neurological and psychological disorders
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
CN102655866B
(en)
|
2009-11-13 |
2013-11-13 |
东丽株式会社 |
Therapeutic or prophylactic agent for diabetes
|
CN102753161A
(en)
|
2009-11-27 |
2012-10-24 |
贝林格尔.英格海姆国际有限公司 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
ES2658168T3
(en)
|
2009-12-15 |
2018-03-08 |
Cirius Therapeutics, Inc. |
PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
|
JP2013520162A
(en)
|
2010-01-22 |
2013-06-06 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Compositions, kits and methods for identification, assessment, prevention and treatment of metabolic disorders
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
WO2011138421A1
(en)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
EP3124041A1
(en)
|
2010-06-24 |
2017-02-01 |
Boehringer Ingelheim International GmbH |
Diabetes therapy
|
EP2611434A1
(en)
|
2010-09-01 |
2013-07-10 |
Lupin Limited |
Pharmaceutical composition comprising metformin and pioglitazone
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
AR083878A1
(en)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
|
SG191399A1
(en)
|
2011-01-10 |
2013-08-30 |
Zinfandel Pharmaceuticals Inc |
Methods and drug products for treating alzheimer's disease
|
WO2012153312A1
(en)
|
2011-05-11 |
2012-11-15 |
Ranbaxy Laboratories Limited |
Process for the purification of pioglitazone
|
ES2713566T3
(en)
|
2011-07-15 |
2019-05-22 |
Boehringer Ingelheim Int |
Derivative of substituted dinamic quinazoline, its preparation and its use in pharmaceutical compositions for the treatment of type I and II diabetes
|
WO2013018899A1
(en)
|
2011-08-03 |
2013-02-07 |
協和発酵キリン株式会社 |
Dibenzooxepin derivative
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
CN104220460A
(en)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
Agonistic human lcat antigen binding proteins and uses thereof in therapy
|
NZ722096A
(en)
|
2011-12-15 |
2016-11-25 |
Alkermes Pharma Ireland Ltd |
Prodrugs of secondary amine compounds
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2638898A1
(en)
|
2012-03-16 |
2013-09-18 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Metformin and Pioglitazone Formulation with Different Release Profiles
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
EP2914250B1
(en)
|
2012-11-05 |
2018-04-04 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
|
CA2941562C
(en)
|
2013-03-14 |
2021-09-21 |
Deuterx, Llc |
Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
|
US20140275138A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Cba Pharma, Inc. |
Method and products for treating diabetes
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
KR102272746B1
(en)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
WO2015042495A2
(en)
*
|
2013-09-22 |
2015-03-26 |
Jiva Pharma, Inc. |
Metformin salts to treat type2 diabetes
|
EP3065757A4
(en)
|
2013-10-09 |
2017-08-23 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
EA201690938A1
(en)
|
2013-11-05 |
2016-11-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
COMPOUNDS FOR THE TREATMENT OF DIABETES AND COMPLICATIONS ARISING OUT OF THIS DISEASE
|
EP3094328B1
(en)
|
2014-01-15 |
2020-08-19 |
Poxel SA |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
ES2950384T3
(en)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Medical use of a DPP-4 inhibitor
|
KR101606547B1
(en)
*
|
2014-06-02 |
2016-03-28 |
김동연 |
Airport passenger position inquiry system
|
MX2017004947A
(en)
|
2014-10-24 |
2017-06-29 |
Bristol Myers Squibb Co |
Modified fgf-21 polypeptides and uses thereof.
|
US10034868B2
(en)
|
2014-11-04 |
2018-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
MA39929A
(en)
|
2014-11-27 |
2016-06-01 |
Arven Ilac Sanayi Ve Ticaret As |
MULTI-LAYER TABLET CONTAINING METFORMIN AND PIOGLITAZONE
|
MY195671A
(en)
|
2016-06-08 |
2023-02-03 |
Support Venture Gmbh |
Pharmaceutical Combinations for Treating Cancer
|
JP2019517542A
(en)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Combination of linagliptin and metformin
|
EP3500258A1
(en)
|
2016-08-17 |
2019-06-26 |
Support-Venture GmbH |
Method of preventing or treating hearing loss
|
TR201620309A2
(en)
|
2016-12-30 |
2018-07-23 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical compositions of metformin hydrochloride and pioglitazone hydrochloride
|
KR20190137854A
(en)
|
2017-04-04 |
2019-12-11 |
스트리킨 아게 |
How to prevent or treat eye diseases
|
WO2019154895A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Gel formulation for preventing or treating hearing loss
|
WO2019154893A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Oral extended release pharmaceutical compositions for preventing or treating hearing loss
|
CN112423754A
(en)
|
2018-03-05 |
2021-02-26 |
奥克梅斯制药爱尔兰有限公司 |
Aripiprazole administration strategy
|
SG11202012775SA
(en)
|
2018-07-13 |
2021-02-25 |
Kinarus Ag |
Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
|
CN111875598B
(en)
*
|
2020-05-23 |
2023-10-10 |
白银京宇新药业有限公司 |
Preparation method of pioglitazone
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
US20230263803A1
(en)
|
2020-08-11 |
2023-08-24 |
Kinarus Ag |
Methods of preventing or treating covid-19 and related viral diseases or disorders
|
AU2021354823A1
(en)
|
2020-09-30 |
2023-03-30 |
Duality Biologics (Suzhou) Co., Ltd. |
Antitumor compound, and preparation method therefor and use thereof
|
EP4385501A1
(en)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor
|
EP4385502A1
(en)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor
|